RxDoctor Payments Data

Luis Flores, MD

Family Medicine · Glendale, CANPI 1760606123

Payments from drug & device makers

$7,762in general payments, 2019–2025

Across 381 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$886
  • Amgen$544
  • AstraZeneca$472
  • Amarin Pharma, Inc.$464
  • Merck$429
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$7,67799%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,762 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$87,905
Medicare patients
158
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate221$150,620
EliquisApixaban179$106,539
OzempicSemaglutide99$96,823
VascepaIcosapent Ethyl235$73,036
JardianceEmpagliflozin89$71,892
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate59$57,156
LinzessLinaclotide87$56,796
Diflorasone Diacetate67$56,149
FarxigaDapagliflozin Propanediol66$52,896
CreonLipase/Protease/Amylase36$50,792
MyrbetriqMirabegron93$50,202
TrulicityDulaglutide48$49,743
Diclofenac Potassium31$45,384
TradjentaLinagliptin49$45,289
Hydrocortisone97$42,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$429$169,022256 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$284$139,672186 claims
Novo NordiskOzempic, Rybelsus$886$122,942119 claims
AbbVieLinzess, Creon$1,330$107,588123 claims
PfizerEliquis$72$106,539179 claims
Lilly USA, LLCTrulicity, Mounjaro$201$91,42988 claims
AstraZenecaFarxiga, Breztri Aerosphere$472$63,74984 claims
Astellas Pharma US IncMyrbetriq$97$50,20293 claims
Otsuka America Pharmaceutical, Inc.Rexulti$297$18,39813 claims
GSKBreo Ellipta$382$10,67828 claims
NovartisEntresto$229$8,40113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →